摘要
目的:评估加兰他敏联合丙戊酸镁治疗阿尔茨海默病(AD)的临床疗效,及对患者血清铜蓝蛋白(CER)、脑源性神经营养因子(BDNF)、mi RNA-132水平的影响,为临床治疗提供依据。方法:116例轻中度AD患者随机分为对照组和观察组各58例。对照组予加兰他敏治疗;观察组在对照组基础上加用丙戊酸镁缓释片。两组疗程均为16周。治疗前后采用简明蒙特利尔认知评估量表(MoCA)、阿尔茨海默病评定量表-认知量表(ADAS-cog)、Blessed-Roth行为量表(BBS)、精神状态检查量表(MMSE)、日常生活功能量表(ADL)等评估两组患者的认知、精神、生活能力,比较两组患者血清CER、BDNF、mi RNA-132水平变化,评价临床疗效和药品不良反应。结果:观察组总有效率显著高于对照组(P<0.05)。治疗后两组MoCA评分较前显著升高(P<0.05),ADAS-cog、BBS、MMSE和ADL量表评分则较前显著下降;且观察组各项量表评分均优于对照组(P<0.05)。治疗后两组血清CER、BDNF、mi RNA-132水平均较前升高(P<0.05),且观察组高于对照组(P<0.05)。两组药品不良反应无明显差异。结论:加兰他敏联合丙戊酸镁治疗通过提高AD患者CER、BDNF、mi RNA-132水平,从而提升患者的学习记忆能力、提高认知功能、改善激越症状,以阻止病情发展、延缓病情恶化、提升其生活质量。
Objective:To evaluate the clinical efficacy of galantamine combined with magnesium valproate in the treatment of Alzheimer’s disease(AD)and its effect on serum ceruloplasmin(CER),brain-derived neurotrophic factor(BDNF)and mi RNA-132 levels,so as to provide reference for clinical treatment.Methods:Totally 116 patients with mild or moderate AD were divided into the control group and the observation group.The control group was orally treated with galantamine,8 mg per time,bid.The observation group was treated with cognitive-promoting drugs and psychosomatic symptom control drugs,namely magnesium valproate sustained release tablets were taken orally on the basis of the control group,0.25 mg,once before sleep,and the dosage was increased to 0.5 mg after one week.The control group was given magnesium valproate tablets orally,and the observation group was given galantamine in combination use.The course of treatment in both groups was 16 weeks,and the cognitive,mental and living abilities of the patients in the two groups were evaluated before and after the treatment,and the clinical efficacy and serological indicators were observed for comparative analysis.Results:The total effective rate of observation group was significantly higher than that of the control group.Montreal cognitive assessment(MoCA)was significantly increased in both groups after the treatment,and the observation group was significantly higher than the control group(P<0.05).Scores of Alzheimer’s disease assessment scale-cognitive section(ADAS-cog),BlessedRoth behavior scale(BBS),mini-mental state examination(MMSE)and activity of daily living scale(ADL)in the two groups were significantly decreased,and the observation group was lower than the control group(P<0.05).CER,BDNF and mi RNA-132 increased after the treatment in both groups,and the observation group was higher than the control group(P<0.05).There were no serious adverse reactions in the two groups.Conclusion:Galantamine combined with magnesium valproate can improve CER,BDNF and mi RNA-132 levels in senile dementia patients,thereby improving their learning and memory ability,cognitive function and agitation symptoms,so as to prevent disease progression,delay disease deterioration and improve their quality of life.
作者
敖小君
朱丽莎
王晓芳
刘若伟
Ao Xiaojun;Zhu Lisha;Wang Xiaofang;Liu Ruowei(Department of Geriatrics,Nanchong Central Hospital,Sichuan Nanchong 637000,China;Department of Clinical Medicine,Nanchong Central Hospital,Sichuan Nanchong 637000,China)
出处
《中国药师》
CAS
2020年第2期303-306,共4页
China Pharmacist
关键词
加兰他敏
丙戊酸镁
阿尔茨海默病
疗效
血清学标志
Galantamine
Magnesium valproate
Alzheimer’s disease
Clinical efficacy
Serological markers
